Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dabomb Protein BiotechROCO:6578 57 Days Payable is 22.86 as of Mar. 2026, which is 63% above its 10-year median of 14.03. GuruFocus rates ROCO:6578 with a GF Score™ of 57/100 and a GF Value™ of NT$16.56 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,888 Consumer Packaged Goods companies, Dabomb Protein Biotech ranks worse than 83.69% on this metric.
The historical rank and industry rank for Dabomb Protein Biotech's Days Payable or its related term are showing as below:
ROCO:6578'
s Days Payable Range Over the Past 10 Years
Min: 8.33 Med: 14.03 Max: 20.79
Current: 20.79
During the past 13 years, Dabomb Protein Biotech's highest Days Payable was 20.79. The lowest was 8.33. And the median was 14.03.
ROCO:6578's Days Payable is ranked worse than 83.69% of 1888
companies
in the Consumer Packaged Goods industry
Industry Median: 43.945
vs ROCO:6578: 20.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Days Payable vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Dabomb Protein Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Days Payable of 22.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dabomb Protein Biotech and its competitors. This is 63% above median its historical median of 14.03. Over the past decade, Dabomb Protein Biotech's Days Payable has ranged from 8.33 to 20.79. According to the industry distribution chart, Dabomb Protein Biotech ranks #1580 out of 1888 companies in the Consumer Packaged Goods industry, placing it in the top 83.7%.
Is Dabomb Protein Biotech's Days Payable too high?
Dabomb Protein Biotech's current Days Payable of 22.86 is 63% above median its 10-year median of 14.03. Over the past 10 years, this metric has ranged from a low of 8.33 to a high of 20.79. The Consumer Packaged Goods industry median Days Payable is 43.95. Dabomb Protein Biotech's value of 22.86 is 48% below this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #1580 out of 1888 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Days Payable compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #1580 out of 1888 companies for Days Payable. This places Dabomb Protein Biotech in the lower half of its industry. The industry median Days Payable is 43.95. Dabomb Protein Biotech's value of 22.86 is 48% below this benchmark. Historically, Dabomb Protein Biotech's own Days Payable has ranged from 8.33 to 20.79 over the past decade. While the company's 10-year median is 14.03 vs. the industry median of 43.95, Dabomb Protein Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Consumer Packaged Goods company?
The median Days Payable among Consumer Packaged Goods companies is 43.95, based on 1,888 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current Days Payable of 22.86 is 48% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median Days Payable is 43.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Days Payable is 22.86, which is 63% above median its own 10-year median of 14.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$16.56, compared to a current price of NT$18.80 — trading 13.5% above its estimated fair value. The current Days Payable is 22.86, which is 63% above median its 10-year median of 14.03 and 48% below the Consumer Packaged Goods industry median of 43.95. Dabomb Protein Biotech's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Days Payable is 22.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$18.80 is trading 13.5% above its estimated GF Value™ of NT$16.56.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
Days Payable: 22.86 (63% above median its 10-year median of 14.03)
GF Value™: NT$16.56 vs. price of NT$18.80 (13.5% above fair value)
Industry Position: 48% below the Consumer Packaged Goods median (#1580 of 1888)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
57GF Score
Get the complete analysis for ROCO:6578
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
